Showing results (571-580 of 1,303) with videos related to
Sort By:
Pageof 131
Journal of Gynecologic Oncology|May 20, 2024
Targeting BRAF pathway in low-grade serous ovarian cancerChiara Perrone, Roberto Angioli, Daniela Luvero, et al.Journal of Gynecologic Oncology|May 24, 2024
Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancerChinmoy K Bose, Nirban BasuJournal of Gynecologic Oncology|April 12, 2024
Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)Yusuke Kobayashi, Muneaki Shimada, Masato Tamate, et al.Journal of Gynecologic Oncology|April 12, 2024
SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinomaYalong Deng, Lu Zhang, Changyuan Dai, et al.Journal of Gynecologic Oncology|April 26, 2024
Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country settingWichai Termrungruanglert, Nipon Khemapech, Apichai Vasuratna, et al.Journal of Gynecologic Oncology|January 23, 2026
Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028)Uisuk Kim, Jaekyung Bae, E Sun Paik, et al.Journal of Gynecologic Oncology|January 9, 2026
Utility of iRECIST for evaluating treatment efficacy in patients receiving immune checkpoint inhibitorsGenta Irie, Yusuke Kobayashi, Ayumi Shikama, et al.Journal of Gynecologic Oncology|December 11, 2025
Pattern of first recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapyJi Hyun Kim, Eun Taeg Kim, Heon Jong Yoo, et al.Journal of Gynecologic Oncology|November 28, 2025
Cost-effectiveness of HPV catch-up vaccination program in women aged 13-24 years in a middle income countryTanitra Tantitamit, Apichai Vasuratna, Nipon Khemapech, et al.Journal of Gynecologic Oncology|December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.Pageof 131